Full definition
AI governance in healthcare is the discipline of making clinical and operational AI systems trustworthy. The core elements: documented model cards (purpose, training data, performance metrics, intended use, contraindications), evaluation harnesses (continuous testing against holdout data and edge-case scenarios), drift monitoring (alerts when model behaviour changes vs baseline), bias audits (performance equity across patient subgroups), human-in-the-loop overrides at every decision point, and audit trails on every AI inference for governance and continuous improvement.
AI governance is what distinguishes credible production-grade healthcare AI from research demos and vapourware. A model that achieves AUC 0.85 in a paper but has no documented model card, no drift monitoring, no bias audit, and no override mechanism is not safe to deploy in clinical operations. Regulators are catching up — FDA SaMD guidance, EU AI Act, and several national frameworks now require elements of AI governance for clinical-decision-support tools.
For a clinic platform that uses AI: governance is non-negotiable. MOVO-X documents every AI feature with a model card, runs evaluation harnesses on each release, monitors drift in production, and provides human override at every decision point. Audit logs capture every AI inference + the clinician's response (accept / override / modify) for governance and continuous improvement.
Where ai governance in healthcare is used
- Clinical decision-support systems
- AI triage and acuity scoring
- No-show prediction and demand forecasting
- NLP-driven clinical documentation
- Predictive risk-stratification
- Computer-vision identity verification
Types of ai governance in healthcare
Model card
Document — purpose, training data, performance, intended use, contraindications.
Evaluation harness
Continuous testing of model behaviour against holdout and edge cases.
Drift monitoring
Production monitoring of model behaviour vs baseline.
Bias audit
Subgroup performance equity assessment.
Human-in-the-loop
Clinician override + audit trail at every decision point.
Algorithmic impact assessment
Pre-deployment review of risk and mitigation.
Quantified benefits
- ▸Trustworthy production AI vs research-demo vapourware
- ▸Regulatory pathway for SaMD-classified features
- ▸Continuous improvement loop via audit trails
- ▸Bias detection and mitigation
Frequently asked
Is AI governance regulated?+
Increasingly — FDA SaMD guidance, EU AI Act, several national frameworks. Specific requirements depend on the AI feature's clinical use and autonomy. Most clinical-decision-support that augments clinician judgment falls below the highest tier; autonomous classification triggers full regulatory pathway.
Does MOVO-X have model cards?+
Yes — every AI feature ships with a model card documenting purpose, training data, performance metrics, intended use, and contraindications. Available to enterprise customers on request.
How do you handle bias in models?+
Pre-deployment bias audits across patient subgroups (age, gender, language, ethnicity where data permits). Post-deployment monitoring for performance drift across subgroups. Issues trigger model retraining or scope restriction.
What about explainability?+
For decision-support features, the AI signal is paired with the underlying drivers visible to the clinician. The clinician can see why the model surfaced a recommendation and decides whether to accept, override, or modify.
Who is responsible if AI gets it wrong?+
Production-grade AI is decision-support — the licensed clinician retains responsibility. Audit trails capture the AI signal + the clinician's action. The goal is augmentation, not replacement; responsibility tracks accordingly.